

## Gujarat Themis Biosyn Limited

October 07, 2024

| Facilities/Instruments     | Amount (₹ crore) | Rating <sup>1</sup> | Rating Action |
|----------------------------|------------------|---------------------|---------------|
| Long-term bank facilities  | 2.00             | CARE BBB; Stable    | Reaffirmed    |
| Short-term bank facilities | 3.00             | CARE A3+            | Reaffirmed    |

Details of instruments/facilities in Annexure-1.

### Rationale and key rating drivers

Reaffirmation of ratings assigned to bank facilities of Gujarat Themis Biosyn Limited (GTBL) factors in satisfactory financial profile and operational performance amidst dependency on a few products. Ratings continue to derive strength from the experienced and qualified promoters and management team, the niche product offerings despite high dependency on a few products, the accredited manufacturing facilities, the healthy profit margins and comfortable capital structure, and debt coverage indicators. However, ratings continue to be constrained by the moderate scale of operations, the working capital-intensive operations, project execution and funding risk associated with capital expenditure undertaken to set up Active Pharmaceutical Ingredients (API) unit and addition of fermentation capacity expansion, customer and supplier concentration risk, the intense competition and presence in a fragmented industry, and the profitability margins susceptible to raw material prices.

### Rating sensitivities: Factors likely to lead to rating actions.

#### Positive factors

- Increasing scale of operations marked by total operating income (TOI) exceeding ₹250 crore while maintaining operating profitability at present level on a sustained basis.
- Successful completion of capex without cost and time overrun and subsequent stabilisation and commercialisation of API fermentation unit.

#### Negative factors

- Deteriorating overall gearing beyond 1x on a sustained basis.
- Substantially deteriorating profitability leading to build up stretch in the company's liquidity profile amidst capex execution.
- Inability of the company to complete of project in timely manner resulting in substantial cost overrun impacting liquidity and credit metrics of the company.

### Analytical approach: Standalone

#### Outlook: Stable.

CARE Ratings Limited (CARE Ratings) expects to sustain its moderate scale of operations with healthy operating profitability in the near term and also expects timely commercialisation of API unit and addition of fermentation capacity to upscale the performance as envisaged.

### Detailed description of key rating drivers

#### Key strengths

##### Experienced and qualified promoters and management team

GTBL is actively managed by promoters of Themis Medicare Limited (TML) since 2007. Dr Dinesh Patel is the Executive Vice Chairman, and his son, Dr Sachin Patel, Managing Director & CEO, has a PhD in Medicinal Chemistry by qualification. He has been the recipient of several industrial accolades. Dr Sachin Patel holds a doctorate in Biological Chemistry from Christ's College, University of Cambridge, in the UK. The promoters are supported by a well-qualified and experienced second-tier management.

#### Niche product offerings, despite high dependency on a few products

The company is engaged in manufacturing intermediates, namely, Rifamycin S and Rifamycin O, using the fermentation process. Rifamycin S is an intermediate for manufacturing drug Rifampicin and Rifamycin O is an intermediate for manufacturing drug, Rifaximin. Rifamycin is used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease. Rifaximin is used for the treatment of diarrhoea, irritable bowel syndrome, and hepatic encephalopathy. Owing to its complex fermentation capabilities with high capex involved, there is limited entry barrier.

<sup>1</sup>Complete definition of ratings assigned are available at [www.careedge.in](http://www.careedge.in) and other CARE Ratings Limited's publications.

### Raw material sourcing and accredited manufacturing facilities

GTBL's key raw material is Rifabutin, which is sourced through the domestic market. The company has long-standing relationships with its suppliers, ensuring the timely supply of key raw materials. The company's manufacturing plant is in Vapi, Valsad district, Gujarat, and the same is Current Good Manufacturing Practice (CGMP)-approved. The company has an installed capacity for manufacturing 216,000 kg of Rifamycin S and Rifamycin O per annum.

### Healthy profit margins

The company's profit before interest, lease rentals, depreciation, and taxation (PBILDT) margin continued to remain healthy and between 45%-50% in last three year ending FY24. It moderated to 46.85% in FY24 against 49.82% in FY23 considering increase in employee cost, increase in cost of material and increase in cost of research and development. However, sales realisation improved to ₹7,556/Kg sold in FY24 compared to ₹7,469/Kg sold in FY23. It achieved PBILDT margin of 48.49% in Q1FY25 compared to 48.54% in Q1FY24.

PAT margin also remained healthy and between 34% and 38% for last three years ended FY24. It moderated to 34.77% in FY24 against 38.91% in FY23 considering increase in depreciation cost considering addition of machineries and increase in leased assets in FY24. GTBL reported profit after tax (PAT) margin of 33.65% in Q1FY25 compared to 34.98% in Q1FY24.

### Comfortable capital structure and debt coverage indicators

GTBL's capital structure continued to remain comfortable with minimal outstanding debt in form of lease liability of ₹2.77 crore compared to sizable net worth base of ₹201.38 crore as on March 31, 2024. Working capital bank borrowing also remained unutilised. Therefore, overall gearing of 0.01x as on March 31, 2024 against 0.0028x as on March 31, 2023.

The company's debt coverage indicators continued to remain comfortable with interest coverage ratio remained at 220.27x in FY24 against 369.79x in FY23 considering marginal increase in interest cost. Further, total debt to gross cash accruals (GCA) also moderated marginally to 0.04x in FY24 against 0.01x in FY23 considering increase total debt in FY24.

However, with availment of the proposed term loan of ₹75 crore, the capital structure and debt coverage indicators are expected to be moderated in the near to medium terms. Nevertheless, the same will continue to remain comfortable on the back of sizable GCA levels.

### Key weaknesses

#### Moderate scale of operations

GTBL's scale of operation continues to remain moderate, however, grew by 12% and it reported TOI to ₹170.15 crore in FY24 against ₹148.97 crore in FY23 considering increase in quantity sold (224723 kg in FY24 from 198313 kg in FY23) primarily led by spillover of inventory in Q4FY23 which got sold in Q1FY24 and increase in sales price in FY24. Resultantly, the company's TOI declined to ₹39.35 crore in Q1FY25 compared to ₹50.66 crore in Q1FY24. Despite the growth in scale of operation it continues to remain moderate. The company expects its revenue continue to remain at the similar levels due to optimum utilisation of its existing capacities. Nevertheless, the growth in the revenue is entirely depending upon the successful completion and stabilisation of the API manufacturing project within envisaged timelines.

#### Working capital-intensive nature of operations

GTBL's operation continues to remain working capital intensive. However, it improved to 34 days in FY24 against 67 days in FY23, mainly considering decrease in outstanding inventory to ₹3.33 crore as on March 31, 2024 from 14.62 crore as on March 31, 2023. The same led to decrease in average inventory period to 36 days in FY24 from 63 days in FY23. Company offers credit period of one to two months leading to collection of 48 days in FY24 compared to 52 days in FY23. On the other hand, average creditors' period of 50 days in FY24 compared to 48 days in FY23. Therefore, operations remained working capital intensive and working capital requirement is met through healthy GCA therefore utilisation of working capital bank borrowings of ₹2 crore remains minimal.

#### Project execution and funding risk

The company has undertaken forward integration project of setting up API manufacturing unit and developing products, namely, Rifapentine and Rifamycin, and addition of more fermenters for expansion in its intermediates manufacturing at its existing plant. The land for the same is already in place.

The company has been executing project of setting up of API unit since Q1FY23 which was supposed to be operational by October 2023, however, it got delayed. However, as informed by management, there was no cost overrun in the project. It is now expected to be operational by April 2025.

The project's total estimated cost is ₹183.04 crore and entire project cost is to be funded through internal accruals. Currently, the company has incurred ₹116.71 crore as on August 31, 2024 (₹29.22 crore incurred as on June 08, 2023) towards the project execution.

The company has also planned to add fermenters for expansion in its intermediates manufacturing to meet raw material requirement for APIs. The project's total estimated cost of the project is ₹160 crore out of which ₹85 crore will be funded through internal accrual and rest ₹75 crore to be funded by term loan (yet to be sanctioned).

The project execution is at nascent stage and company has incurred ₹9.70 crore as on August 31, 2024, towards the project execution. Project execution was commenced in Q1FY25 and expected to be operational in FY26.

Thus, going forward, GTBL's ability to complete the project without cost and time overrun and subsequent stabilisation of the same remains critical from credit perspective.

### Customer and supplier concentration risks

The company caters to two major customers, Lupin Limited, contributing 61% of the sales, and Oprix Laboratories Private Limited, contributing the balance 37% of sales. The company has a 'take or pay' agreement with Oprix Laboratories Private Limited, which is renewed annually, and has a contract with Lupin Limited for five years, hence, concentration risk is mitigated to an extent. Per the contract clause, it is on a 'take or pay' basis, hence, the company is completely protected in supply. However, major setback in the financial profile of these clients can significantly impact the growth of GTBL. The company's supplier profile also remained concentrated, with the top 10 suppliers contributing 84% of the total purchases in FY24 against 83% of the total purchases in FY23.

### Intense competition and presence in a fragmented industry; profitability margins susceptible to raw material prices

GTBL's profitability margins are susceptible to raw material price volatility. Moreover, the Indian pharmaceutical industry (IPI) comprises mainly of formulations, APIs, and contract research and manufacturing services (CRAMS) segments. Although IPI has shown a healthy growth, the industry remains highly competitive. By volume, Indian companies produce about one-fifth of the global generic medicines, nearly half of which was by way of exports, witnessing increasing competition.

### Liquidity: Adequate

The liquidity position remained adequate marked by sufficient cushion in internal accruals and free cash and bank balance including free fixed deposits against repayment obligations and funding for capex in FY25 and FY26. The working capital requirement is also managed through internal accruals therefore average utilisation of working capital bank borrowings of ₹2 crore remain nil in past 12 months ended August 2024. The current ratio and quick ratio stood comfortable at 4.96x and 4.76x, respectively, as on March 31, 2024 (against 6.70x and 5.74x, respectively, as on March 31, 2023). Cash flow from operating activities stood positive of ₹104.27 crore in FY24 (against ₹10.26 crore in FY23).

### Applicable criteria

[Definition of Default](#)

[Liquidity Analysis of Non-financial sector entities](#)

[Rating Outlook and Rating Watch](#)

[Manufacturing Companies](#)

[Pharmaceuticals](#)

[Financial Ratios – Non financial Sector](#)

[Short Term Instruments](#)

### About the company and industry

#### Industry classification

| Macroeconomic indicator | Sector     | Industry                        | Basic industry  |
|-------------------------|------------|---------------------------------|-----------------|
| Healthcare              | Healthcare | Pharmaceuticals & biotechnology | Pharmaceuticals |

GTBL was incorporated in 1981 and is engaged in manufacturing APIs, namely, Rifamycin S and Rifamycin O. Rifamycin S is an intermediate for manufacturing drug, Rifampicin (antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease). Rifamycin O is an intermediate for manufacturing drug Rifaximin (antibiotic used for the treatment of traveller's diarrhoea, irritable bowel syndrome, and hepatic encephalopathy). These are niche products. The company's manufacturing plant is in Vapi, Valsad district, Gujarat, and the same is CGMP-approved.

| Brief Financials (₹ crore) | March 31, 2023 (A) | March 31, 2024 (A) | June 30, 2024 (UA) |
|----------------------------|--------------------|--------------------|--------------------|
| Total operating income     | 148.97             | 170.15             | 39.35              |
| PBILDT                     | 74.22              | 79.72              | 19.08              |
| PAT                        | 57.97              | 59.16              | 13.24              |
| Overall gearing (times)    | 0.00               | 0.01               | NA                 |
| Interest coverage (times)  | 369.79             | 220.27             | 272.57             |

A: Audited, UA: Unaudited, NA: Not available, Note: These are latest available financial results.

**Status of non-cooperation with previous CRA:** Not applicable

**Any other information:** Not applicable

**Rating history for last three years:** Annexure-2

**Covenants of rated instruments/facilities:** Annexure-3

**Complexity level of instruments rated:** Annexure-4

**Lender details:** Annexure-5

#### Annexure-1: Details of instruments/facilities

| Name of the Instrument    | ISIN | Date of Issuance (DD-MM-YYYY) | Coupon Rate (%) | Maturity Date (DD-MM-YYYY) | Size of the Issue (₹ crore) | Rating Assigned and Rating Outlook |
|---------------------------|------|-------------------------------|-----------------|----------------------------|-----------------------------|------------------------------------|
| Fund-based-Long Term      |      | -                             | -               | -                          | 2.00                        | CARE BBB; Stable                   |
| Non-fund-based - ST-BG/LC |      | -                             | -               | -                          | 3.00                        | CARE A3+                           |

#### Annexure-2: Rating history for last three years

| Sr. No. | Name of the Instrument/Bank Facilities | Current Ratings |                              |                  | Rating History                              |  |   |   |
|---------|--|-----------------|------------------------------|------------------|---|--|---|---|
|         |  | Type            | Amount Outstanding (₹ crore) | Rating           | Date(s) and Rating(s) assigned in 2024-2025 | Date(s) and Rating(s) assigned in 2023-2024                      | Date(s) and Rating(s) assigned in 2022-2023 | Date(s) and Rating(s) assigned in 2021-2022 |
| 1       | Fund-based-Long Term                   | LT              | 2.00                         | CARE BBB; Stable | -   | 1)CARE BBB; Stable (25-Sep-23)<br>2)CARE BBB; Stable (04-Aug-23) | 1)CARE BBB; Stable (04-Aug-22)              | 1)CARE BBB-; Stable (07-Jul-21)             |
| 2       | Non-fund-based - ST-BG/LC              | ST              | 3.00                         | CARE A3+         | -   | 1)CARE A3+ (25-Sep-23)<br>2)CARE A3+ (04-Aug-23)                 | 1)CARE A3+ (04-Aug-22)                      | 1)CARE A3 (07-Jul-21)                       |

LT: Long term; ST: Short term

#### Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not available

**Annexure-4: Complexity level of instruments rated**

| Sr. No. | Name of the Instrument    | Complexity Level |
|---------|---------------------------|------------------|
| 1       | Fund-based-Long Term      | Simple           |
| 2       | Non-fund-based - ST-BG/LC | Simple           |

**Annexure-5: Lender details**

To view lender-wise details of bank facilities please [click here](#)

**Note on complexity levels of rated instruments:** CARE Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to [care@careedge.in](mailto:care@careedge.in) for clarifications.

## Contact us

|   |   |
|---|---|
| <b>Media Contact</b><br><br>Name: Mradul Mishra<br>Director<br><b>CARE Ratings Limited</b><br>Phone: +91-22-6754 3596<br>E-mail: <a href="mailto:mradul.mishra@careedge.in">mradul.mishra@careedge.in</a>           | <b>Analytical Contacts</b><br><br>Name: Akhil Goyal<br>Director<br><b>CARE Ratings Limited</b><br>Phone: +91-22 6754 3590<br>E-mail: <a href="mailto:akhil.goyal@careedge.in">akhil.goyal@careedge.in</a> |
| <b>Relationship Contact</b><br><br>Ankur Sachdeva<br>Senior Director<br><b>CARE Ratings Limited</b><br>Phone: 91 22 6754 3444<br>E-mail: <a href="mailto:ankur.sachdeva@careedge.in">ankur.sachdeva@careedge.in</a> | Name: Ashish Kambli<br>Associate Director<br><b>CARE Ratings Limited</b><br>Phone: +91 - 22 - 6754 3597<br>E-mail: <a href="mailto:Ashish.k@careedge.in">Ashish.k@careedge.in</a>                         |
|   | Name: Aditya Bhujbal<br>Analyst<br><b>CARE Ratings Limited</b><br>E-mail: <a href="mailto:aditya.bhujbal@careedge.in">aditya.bhujbal@careedge.in</a>  |

### About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

### Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For detailed Rationale Report and subscription information,  
please visit [www.careedge.in](http://www.careedge.in)**